3 New available positions at PERSIMUNE and CHIP
Statement by the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents Regarding Results
With the availability of the START and TEMPRANO trial results, the Panel’s overall recommendation remains the same: ART is recommended for all HIV-infected patients regardless of pre-treatment CD4 count. However, the strength of the recommendation will be changed to AIa (strong recommendation based on data from randomized controlled trials) for all patients. STATEMENT
Presentation from IAS 2015 now available online!
CHIP was represented at IAS 2015 with the following presentation: "Excess TB mortality in HIV patients in Eastern Europe: restructured approach to care needed". Find it HERE.
Read the latest news about the START study results
Article on START study results in New England Journal of Medicine
Read the article on the groundbreaking results of the START study on the benefits of early antiretroviral treatment. Now available online
Live Streaming from IAS2015 Press Conference on START study results
Follow the live streaming from IAS2015 press conference for the presentation of the groundbreaking results from the START study
8th IAS Conference on HIV Pathogenesis, Treatment and Prevention 19-22 July 2015
The START study: Design, conduct and main results
Presented by Jens Lundgren, Rigshospitalet, University of Copenhagen, Denmark
Monday 20th July 11-12.30 Ballroom A, Session title: The Strategic Timing of Antiretroviral Treatment (START) Study: Results and their Implications.
Excess TB mortality in HIV patients in Eastern Europe: restructured approach to care needed. Presented by Anna Schultze on behalf of the TB:HIV study group in EuroCoord.
Monday 20th July 11:30-11:45 Ballroom C-D. Session Title: HIV and TB: Gaps and Opportunities. Abstract number MOAB0203.
Community-based HIV rapid testing and linkage to care. Efficacy of multi-country testing initiatives during European testing week 2014
Presented by Anna Zakowicz
Wednesday 22nd July 12.30-14, Exhibition located in Hall B on West Exhibition Level, Poster number: WEPEC672
BREAKING NEWS: Results of the START study
START, one of the largest ongoing HIV studies, has announced early results regarding the long-debated question of when to start HIV-infected individuals on treatment.
Read the press release from the NIH here.
Have questions about the study results and what they mean for HIV patients? Find answers on the NIH Q & A page.
Go to CHIP's START news page or click on the links below to read what other news sources around the world are saying about the groundbreaking results of the START study:
The New York Times
25th ECCMID, Copenhagen, Denmark, 25-28 April 2015.
"The indications for Transplantation (TX) : a risk factor for ALT-flares and death during post-transplant follow up (FU)" . Presented by Louise Lundgren. Authors: Louise Lundgren*, Caspar Da Cunha-Bang, Amanda Mocroft, Lars Vindeløv, Finn Gustafsson, Martin Iversen, Nikolai Kirkby, Jens Dilling Lundgren, Allan Rasmussen, Søren Schwartz Sørensen, Henrik Sengeløv – on behalf of the MATCH study group.
Saturday 25th April 15.30-16.30CET, Poster number: P0266, Poster session: Infections in Organ Transplant Recipients (P14)
"High Proportion of Symptomatic CMV Infection Despite Optimal Practice of a Preemptive CMV Strategy for Recipients of Solid Organ Transplantation (SOT) and Hematopoietic Stem Cell Transplantation (HSCT)" Presented by Isabelle Lodding. Authors: I. Lodding, C. Da-Cunha Bang, H. Sengeløv, M. Iversen, A. Rasmussen, L. Vindeløv, F. Gustafsson, N. Kirkby, A. Mocroft, S. Schwartz Sørensen, J. Lundgren on the behalf of the MATCH programme study group.
Monday 27th of April 15:15CET. abstract
First PERSIMUNE article
Chairman’s poster prize for EuroSIDA poster
The poster: Rate of Accumulation of Drug Resistance Mutations during Virological Failure According to Different Measures of Viral Load Exposure was awarded the Chairman’s Poster Prize at the XXIV International Drug Resistance Workshop, 21-22 February, Seattle, Washington. See poster here
Presentations from CROI 2015 now available online!
CHIP was represented at CROI 2015 with presentations from the EuroSIDA study, the D:A:D study and INSIGHT. Find them all HERE.
EuroSIDA at CROI 23rd-26th February 2015
EuroSIDA will be represented at the annual Conference on Retroviruses and Opportunistic Infections (CROI) with the following presentations:
"A Prognostic Score Estimating the Risk of Liver-Related Death Among HIV/HCV Coinfected Subjects", presented by Amanda Mocroft, submitting author: Daniel Grint. Session P-N1, February 24th 2.30-4.00 PM. Abstract number 637.
"New Marker of Standard-of-ART Care: Percentage of Time on cART With Suppressed HIV-RNA", presented by Kamilla Laut. Session P-K2, February 24th 2.30-4.00PM. Abstract number 561.
DR News explains how PERSIMUNE and 60 million danish kroners will help determine why some people can't tolerate chemotherapy or organ transplantations article (in Danish)